Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Zacras AG Now Available, Aloxi AG Expected for September Launch
June 18, 2021
- Kyowa Adjusting Cymbalta Generic Supply before Launch as Rivals Delay Release
June 18, 2021
- Nichi-Iko Licenses Its Remicade Biosimilar to Argentine Drug Maker
June 18, 2021
- Delays in Cymbalta Generic Launch Stir Worries on Demand Spike for 2 Makers
June 17, 2021
- Astellas Offloads 5 Legacy Products to Germany’s Cheplapharm
June 17, 2021
- Daiichi Sankyo Ships AstraZeneca COVID-19 Vaccine to Taiwan, Vietnam
June 17, 2021
- Kitasato Institute, Meiji Eye Ivermectin Derivative Use for Post-COVID-19 Symptoms Too
June 16, 2021
- Enhertu Enters PIII for 1st Line HER2-Positive Breast Cancer
June 16, 2021
- Daiichi Sankyo Drops Nafamostat Development for COVID-19
June 16, 2021
- Rohto Initiates Japan PII of Stem Cell Therapy for Severe COVID-19 Pneumonia
June 16, 2021
- Eisai to Transfer Zonegran’s European Rights to UK Firm
June 16, 2021
- Shipment Curbs of 3,000-Plus Products Taking a Toll on Wholesalers as Generic Woes Continue
June 15, 2021
- Opdivo Gets 2 New Indications in South Korea: Ono
June 15, 2021
- Honjo Ups Royalty Claim after Tecentriq Settlement: Opdivo Row
June 14, 2021
- Japan Approves J-TEC’s Mucosal Cell Sheet for Corneal Stem Cell Deficiency
June 14, 2021
- Chugai Files Bispecific Antibody Faricimab for DME, nAMD in Japan
June 14, 2021
- Japan Approves 1st Oncolytic Virus, Delytact, for Malignant Glioma
June 14, 2021
- Ono to Ditch Foipan Development for COVID-19 as it Misses Goal in Japan PIII
June 14, 2021
- Astellas, Otsuka, Meiji Joining Workplace Vaccination Campaign
June 11, 2021
- NanoCarrier Gene Therapy VB-111 Enters PIII in Japan
June 11, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…